Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201971 | 0.89 | CHRM1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL30201963 | 0.88 | HTR5A (0.35) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL30202021 | 0.86 | CHRM1 (0.32) | CHRM1LMNAHTR5A | |
| SCHEMBL30202074 | 0.83 | HTR5A (0.37) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL23881540 | 0.82 | GABRA1 (0.49) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL30202084 | 0.82 | CHRM1 (0.49) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL23881519 | 0.82 | CHRM1 (0.49) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL30133111 | 0.82 | GABRA1 (0.49) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL23927165 | 0.77 | CHRM1 (0.46) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL23927144 | 0.77 | GABRA1 (0.51) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4139310-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRB3 | GABRA1 1/4885GABRA5 9/4885GABRA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.